BR112017019241A2 - análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico - Google Patents

análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico

Info

Publication number
BR112017019241A2
BR112017019241A2 BR112017019241A BR112017019241A BR112017019241A2 BR 112017019241 A2 BR112017019241 A2 BR 112017019241A2 BR 112017019241 A BR112017019241 A BR 112017019241A BR 112017019241 A BR112017019241 A BR 112017019241A BR 112017019241 A2 BR112017019241 A2 BR 112017019241A2
Authority
BR
Brazil
Prior art keywords
peptide analog
inducing
infection
kit
compound
Prior art date
Application number
BR112017019241A
Other languages
English (en)
Inventor
Vennerstrom Jonathan
d sanderson Sam
Original Assignee
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska filed Critical Univ Nebraska
Publication of BR112017019241A2 publication Critical patent/BR112017019241A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1745—C-reactive proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

análogos peptídicos conformacionalmente estáveis do agonista de c5a resposta-seletivo ep57 possuindo a fórmula tir-ser-fen-lis-asp-met-xaa- (xaa2)-(d-ala)-arg (seq id no: 1), em que xaa é um resíduo de prolina modificado ou uma substituição de resíduo para prolina, e xaa2 é leucina ou n-metil-leucina. os peptídeos conformacionalmente estáveis se ligam e ativam seletivamente apcs sem engajar/ligar diretamente nas células possuindo receptores c5a envolvidas em atividades pró-inflamatórias da c5a natural. também são descritas composições e métodos de uso dos análogos peptídicos.
BR112017019241A 2015-03-11 2016-03-11 análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico BR112017019241A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131393P 2015-03-11 2015-03-11
PCT/US2016/022103 WO2016145365A1 (en) 2015-03-11 2016-03-11 Conformationally stable analogs of the response selective c5a agonist ep67

Publications (1)

Publication Number Publication Date
BR112017019241A2 true BR112017019241A2 (pt) 2018-05-08

Family

ID=56878905

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019241A BR112017019241A2 (pt) 2015-03-11 2016-03-11 análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico

Country Status (8)

Country Link
US (1) US20180066018A1 (pt)
EP (1) EP3267980A4 (pt)
CN (1) CN107847452A (pt)
AU (1) AU2016228771A1 (pt)
BR (1) BR112017019241A2 (pt)
CA (1) CA3016420A1 (pt)
WO (1) WO2016145365A1 (pt)
ZA (1) ZA201706638B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018284219A1 (en) * 2017-06-12 2020-01-16 Board Of Regents Of The University Of Nebraska Hydrochloride salts of C5a receptor agonist peptides
WO2019154515A1 (en) 2018-02-09 2019-08-15 The Cyprus Foundation For Muscular Dystrophy Research Methods and compositions for the treatment of amyloid diseases
EP3849590A4 (en) * 2018-09-14 2022-09-28 Prommune, Inc. ANTIPARASITIC IMMUNOLOGICAL COMPOSITIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
ATE399022T1 (de) 1995-10-20 2008-07-15 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
ES2222728T3 (es) * 1998-10-05 2005-02-01 Pharmexa A/S Procedimiento de vacunacion terapeutica.
JP5421366B2 (ja) * 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
CA2839677A1 (en) 2010-06-29 2012-01-12 Board Of Regents Of The University Of Nebraska Analogs of c5a and methods of using same
DE102011077411B4 (de) 2011-06-10 2018-05-30 Siemens Healthcare Gmbh Verfahren zum Gewinnen von Röntgenbildern
WO2013032964A1 (en) * 2011-08-26 2013-03-07 Board Of Regents Of The University Of Nebraska Compositions and methods for preventing and treating biofilms
WO2013082535A2 (en) * 2011-12-02 2013-06-06 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof

Also Published As

Publication number Publication date
ZA201706638B (en) 2019-01-30
US20180066018A1 (en) 2018-03-08
EP3267980A1 (en) 2018-01-17
CA3016420A1 (en) 2016-09-15
CN107847452A (zh) 2018-03-27
AU2016228771A1 (en) 2017-10-26
WO2016145365A1 (en) 2016-09-15
EP3267980A4 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
MX347200B (es) Péptidos procoagulantes y sus derivados, y usos para estos.
EA200870237A1 (ru) Последовательности пептидов и композиции
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
BR112018000903A2 (pt) composições e métodos para o tratamento de câncer
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
BR112017009405A2 (pt) composições antibióticas.
AU2022204463B2 (en) Novel human serum albumin mutant
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
MY152979A (en) Novel insulin derivatives having an extremely delayed time-action profile
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
UA103015C2 (ru) Новые производные инсулина с чрезвычайно замедленным профилем время/действие
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
EA201990900A1 (ru) Стабильный при комнатной температуре лиофилизированный белок
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
BR112017019241A2 (pt) análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
BR112016026637A2 (pt) associação de um tetrapeptídeo e um gliceril éster para tratamento de alopecia androgênica
TR201902131T4 (tr) Enfeksiyöz bronşit virüsünün (IBV) doku tropizmini uzatan mutant diken proteini.
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
MX2020002552A (es) Métodos y composiciones para preparar proteína surfactante d (sp-d).

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]